POLE and endometrioid adenocarcinoma: The TCGA described in 2022 four molecular subtypes of EC based on genomic characteristics: (1) POLE-mutated (ultra mutated, ≥100 mutations/Mb) tumors are characterized by mutations in the DNA polymerase epsilon (POLE) gene; these mutations lead to distinct characteristics such as high mutational burden, microsatellite stability, significant immune cell infiltration, and generally favorable prognosis [17], and they are often well-differentiated endometrioid carcinomas.